市场调查报告书
商品编码
1404041
尼古丁替代疗法市场规模 - 按产品类型(口香糖、透皮贴片、含片、吸入器、喷雾剂)、给药途径(口服、透皮、鼻腔)、模式(OTC、处方)、配销通路和全球预测,(2024年 -第2032章Nicotine Replacement Therapy Market Size - By Product Type (Gum, Transdermal Patch, Lozenges, Inhaler, Spray), Route of Administration (Oral, Transdermal, Nasal), Mode (OTC, Prescription), Distribution Channel, & Global Forecast, (2024 - 2032) |
由于 FDA 采取积极措施帮助 NRT,全球尼古丁替代疗法市场在 2024 年至 2032 年间的CAGR将达到 8.2%。随着指南和措施的不断发展,FDA 推出了更安全的戒烟替代方案。这些努力推动市场发展,鼓励 NRT 产品的创新和可近性。
例如,2023 年 5 月,美国 FDA 药物评估与研究中心 (CDER) 发布了一份明确指南,帮助申办者开发尼古丁替代疗法 (NRT) 药品以帮助戒烟。该指南根据产品是已批准药物的仿製药还是与现有药物有相似之处,概述了不同的资料要求。大多数申办者预计将透过简化新药申请 (ANDA) 或 505(b)(2) 途径等途径寻求批准,利用该机构对已批准产品的安全性和有效性研究结果。
随着监管支持的增加,对多种 NRT 选择的需求激增,反映出消费者转向更健康的习惯,以及在 FDA 的进步倡议的推动下,更加关注有效的尼古丁替代疗法。
尼古丁替代疗法市场的整体份额根据产品类型、配销通路和地区进行分类。
从 2024 年到 2032 年,含片细分市场将经历重大发展。这些含片提供谨慎且方便的尼古丁输送,可有效帮助戒烟。凭藉其用户友好的形式和可控的剂量,它们迎合了寻求替代吸烟的个人。随着消费者优先考虑易用性和逐步减少尼古丁含量,NRT 市场对含片的需求持续飙升,反映出人们在戒烟过程中越来越偏好实用且易于使用的解决方案。
从 2024 年到 2032 年,零售药局领域的尼古丁替代疗法市场规模将出现显着的复合CAGR。作为可访问且值得信赖的医疗保健产品中心,零售药房迎合寻求尼古丁贴片、口香糖和含片等戒烟辅助工具的消费者。这些商店提供指导和多样化的 NRT 选择,符合消费者对便利和可靠的医疗保健解决方案的偏好。零售药局的强劲需求凸显了它们在向个人提供 NRT 产品和教育个人、促进获取以及帮助吸烟者戒烟方面发挥关键作用。
欧洲尼古丁替代疗法产业将在 2024 年至 2032 年呈现出值得称讚的CAGR。随着对公共卫生倡议和戒烟计划的关注,贴片、口香糖和含片等 NRT 产品获得了发展势头。欧洲消费者越来越多地寻求药房和医疗保健提供者提供的可取得且受监管的 NRT 选择。随着戒烟成为当务之急,该地区对 NRT 辅助品的需求激增,反映出欧洲不同人群为实现更健康的生活方式而共同努力,以及为减少吸烟率而共同努力的结果。
例如,2023 年 9 月,在欧洲呼吸学会国际大会上,调查结果显示,使用伐尼克兰和尼古丁替代含片的住院吸烟者的戒烟率更高。莫纳什大学的 Michael J. Abramson 博士建议,将伐尼克兰与口服尼古丁替代品结合可提高戒烟成功率。联合疗法在报告的结果中显示出有效性,并且耐受性良好,表明对于住院患者戒烟是一种有前景的方法。
Global Nicotine Replacement Therapy Market will witness 8.2% CAGR between 2024 and 2032 due to the FDA's proactive measures in aiding NRTs. With evolving guidelines and initiatives, the FDA promotes safer alternatives for smoking cessation. These efforts drive the market, encouraging innovation and accessibility in NRT products.
For instance, in May 2023, the US FDA's Center for Drug Evaluation and Research (CDER) released a definitive guideline aiding sponsors in developing nicotine replacement therapy (NRT) drug products to aid smoking cessation. The guidance outlined varying data requisites based on whether the product is a generic version of an approved drug or shares similarities with an existing one. Most sponsors are expected to pursue approval through pathways like the abbreviated new drug application (ANDA) or the 505(b)(2) route, leveraging the agency's safety and efficacy findings from approved products.
As regulatory support grows, there's a surge in demand for diverse NRT options, reflecting a consumer shift towards healthier habits and a heightened focus on effective nicotine replacement therapies facilitated by the FDA's progressive initiatives.
The overall Nicotine Replacement Therapy Market share is classified based on the product type, distribution channel, and region.
Lozenges segment will undergo significant development from 2024 to 2032. Offering discreet and convenient delivery of nicotine, these lozenges serve as an effective aid for smoking cessation. With their user-friendly format and controlled dosage, they cater to individuals seeking an alternative to smoking. As consumers prioritize ease of use and gradual nicotine reduction, the demand for lozenges within the NRT market continues to soar, reflecting a growing preference for practical and accessible solutions in the journey toward quitting smoking.
Nicotine replacement therapy market size from the retail pharmacy segment will register a noteworthy CAGR from 2024 to 2032. As accessible and trusted hubs for healthcare products, retail pharmacies cater to consumers seeking smoking cessation aids like nicotine patches, gums, and lozenges. These outlets provide guidance and diverse NRT options, aligning with consumer preferences for convenience and reliable healthcare solutions. The robust demand within retail pharmacies underscores their pivotal role in supplying and educating individuals on NRT products, facilitating access, and aiding smokers in their journey toward quitting.
Europe nicotine replacement therapy industry will showcase a commendable CAGR from 2024 to 2032. With a focus on public health initiatives and smoking cessation programs, NRT products like patches, gums, and lozenges gain momentum. European consumers increasingly seek accessible and regulated NRT options offered through pharmacies and healthcare providers. As smoking cessation becomes a priority, the region experiences an upsurge in demand for NRT aids, reflecting a concerted effort towards healthier lifestyles and a collective drive to reduce smoking prevalence across diverse European populations.
For instance, in September 2023, At the European Respiratory Society International Congress, findings revealed higher quit rates among hospitalized smokers who used varenicline alongside nicotine replacement lozenges. Michael J. Abramson, Ph.D., from Monash University, suggested that combining varenicline with oral nicotine replacement enhances cessation success. The combination therapy showed effectiveness in reported outcomes and was well-tolerated, indicating a promising approach for quitting smoking among hospitalized individuals.